Diamond V A.I CyberSecurity Scoring
04/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Diamond V in 2026.
No incidents recorded for Diamond V in 2026.
No incidents recorded for Diamond V in 2026.
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL
Latest updates, reports, and threat intel affecting the global network.
Landmark designation affirms WEI's leadership in delivering enterprise‑wide cybersecurity outcomes across.
Ahmedabad: When cybersecurity experts analysed a full year of malware activity across India, they expected the usual suspects — the tech...
Deal to focus on key sectors including infrastructure, energy, the diamond industry, agriculture, cybersecurity and defense - Anadolu...
B2B security software is growing faster than overall B2B software sales, according to new figures.
Kirby Inland Marine christened the first plug-in diesel hybrid electric towboat in the U.S., the M/V Green Diamond, on the water in Texas.
Although COVID-19 pandemic is still unfolding, class actions related to the coronavirus are already being filed in banking & Debt collection...
Philadelphia District Attorney Seth Williams pleads guilty to accepting a bribe, ending his ongoing federal corruption trial and his tenure...
The third edition of the Bengal Global Business Summit promises to kick off with a big bang. Global consultancy giant PricewaterhouseCoopers...
Optimize cloud infrastructure with VMware for app platforms, private cloud, edge, networking, and security.
A vulnerability has been found in Dromara lamp-cloud up to 5.10.0. This affects an unknown part of the file DefGenProjectController.java of the component Code Generator. Such manipulation of the argument outputDir/parent/projectPrefix leads to path traversal. It is possible to launch the attack remotely. The exploit has been disclosed to the public and may be used. The project was informed of the problem early through an issue report but has not responded yet.
A vulnerability was detected in Model Context Protocol mcp-rdf-explorer 1.0.0. Affected is the function explore_url of the file src/mcp-rdf-explorer/server.py of the component MCP Server. Performing a manipulation of the argument url results in server-side request forgery. The attack may be initiated remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.
OpenChoreo is a complete, open-source developer platform for Kubernetes. Prior to 1.0.2 and 1.1.2, internal/cluster-gateway/server.go served caller-facing management APIs on the externally reachable agent listener without authentication, allowing network-reachable attackers to invoke /api/proxy/ and /api/exec/ operations, proxy the data-plane Kubernetes API, and execute commands in workload pods in multi-cluster deployments. This issue is fixed in versions 1.0.2 and 1.1.2.
OpenChoreo is a complete, open-source developer platform for Kubernetes. Prior to 1.0.3, 1.1.3, and 1.2.0-rc.2, internal/cluster-gateway/server.go exposed /api/proxy/, /api/exec/, and /api/wirelogs/ on an internal listener without requiring a client certificate or token, allowing any network-reachable caller to read tenant Kubernetes Secrets, mutate workloads, and execute commands across connected data planes. This issue is fixed in versions 1.0.3, 1.1.3, and 1.2.0-rc.2.
OpenChoreo is a complete, open-source developer platform for Kubernetes. From 1.2.0-rc.1 until 1.2.0, internal/openchoreo-api/api/handlers/exec.go and internal/openchoreo-api/api/handlers/wirelogs.go authorize component:exec and wirelogs:view using the caller-supplied project query parameter instead of comp.Spec.Owner.ProjectName, allowing a user with a project-scoped grant to execute commands in and read wirelogs from components owned by other projects in the same namespace. This vulnerability is fixed in 1.2.0.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.